Abstract
Matrix metalloproteinases (MMPs) have received much attention in recent years for their role in a variety of malignancies. Pancreatic cancer is no exception; MMP-2 and MMP-9 show high levels of expression in clinical and experimental models. Inhibition of MMPs has shown great promise with synthetic inhibitors, such as BB-94, as tumorostatic agents in preclinical models, particularly when these are combined with gemcitabine. These findings have led to several clinical trials using the MMP inhibitors Marimastat and BAY12-9566. Herein, we discuss the roles of MMPs and their inhibition in pancreatic cancer.
MeSH terms
-
Animals
-
Antineoplastic Agents / therapeutic use
-
Gene Expression Regulation, Enzymologic
-
Humans
-
Hydroxamic Acids / therapeutic use
-
Matrix Metalloproteinase Inhibitors
-
Matrix Metalloproteinases / genetics
-
Matrix Metalloproteinases / metabolism*
-
Mice
-
Pancreatic Neoplasms / enzymology*
-
Pancreatic Neoplasms / genetics
-
Tissue Inhibitor of Metalloproteinases / genetics
-
Tissue Inhibitor of Metalloproteinases / metabolism
-
Transfection
Substances
-
Antineoplastic Agents
-
Hydroxamic Acids
-
Matrix Metalloproteinase Inhibitors
-
Tissue Inhibitor of Metalloproteinases
-
marimastat
-
Matrix Metalloproteinases